When: Price reaches $255-257 zone (lower Bollinger Band)

Then: Optional third tranche with stop below $255

When: Weekly close below $258.72 (50 SMA) on volume >7M

Then: Exit core position - floor effect has given way

HOLD existing core position; do not add at $275.23; trim if above allocation limit; watch for $255-$260 zone entry with small first tranche only after demonstrating support; await breakout above $279.63 on daily close with volume above 7-8 million shares.

• Revenue growth accelerated to 6.6% in Q2 2026 with gross margin of 68.1% and operating margin of 29.2%
• ROE of 25.7% and 2025 free cash flow of $19.3 billion with net debt to EBITDA of only 0.82 times
• Dividend has grown for 64 years at current 1.93% yield
• Current valuation at $275.23 near 52-week high, trading at 31.9x trailing earnings and 22.4x forward earnings
• Supplied PEG ratio of 4.32 (other report cites 3.0); conservative estimate used
• UBS $320 target represents 16.3% upside ($44.77 per share) but requires bull case probability above 40% to break even
• Downside scenarios: $260 (5.5% decline), $255 (7.4% decline), $245 (11.0% decline)
• Technical resistance at $279.63 upper Bollinger Band; 50-day SMA at $260.72; 200-day area near $234-$235
• RSI of 61.22 and positive MACD are lagging indicators showing current trend, not future direction
• Recent volume of 3.88 million shares vs. norm of 7-8 million lacks confirmation at new high
• Talc litigation remains active with proposed resolution not finished and fresh Louisiana verdict
• Stelara erosion and AbbVie competition represent ongoing revenue risks
• Forward EPS estimate of $12.31 is analyst projection, not realized cash flow
• Long-term revenue growth guidance of 4%-5% and three-year FCF growth of ~6% indicate steady rather than hypergrowth
• Implementation error: proposed stop at $267 is above $260 entry, functioning as profit-taking rather than loss protection

→ vs aggressive: Pipeline argument is plausible but remains a forecast; strong ROE justifies premium to mediocre companies but not any premium regardless of price

→ vs aggressive: Single analyst $320 target is not risk-adjusted expected value; assumes successful pipeline execution, continued Carvykti growth, favorable Stelara treatment, stable rates, and no adverse litigation

→ vs aggressive: Immediate 1.6% move to upper Bollinger Band is not substitute for proper expected-value analysis; 50-day SMA is not guaranteed floor

→ vs aggressive: Risk of inaction does not equal risk of buying now; opportunity cost is not equivalent to capital loss; missing 5% pullback is inconvenient but adding into weak-volume expensive setup creates loss taking years of dividends to recover

→ vs neutral: Statement that bull and bear cases cancel out is not adequate risk conclusion; absence of reason to trim is not reason to add

HOLD core position with staged three-tranche add: 1/3 now at ~$275 with stop below $270 on closing basis; 1/3 reserved for pullback to $260-$263 with stop below $257; 1/3 reserved for confirmed close above $279.63 on volume above 7-8M shares

• Quality metrics support continued ownership: 25.7% ROE, 64-year dividend streak, 6.6% revenue acceleration in recent quarter, sector-leading margins, beta 0.23
• UBS $320 price target is a 12-18 month point estimate, not an expected value—probability of success matters significantly
• Declining volume (3.88M shares vs 7-8M norm) at resistance is a real signal, not necessarily accumulation
• Talc litigation risk not fully priced by fresh Louisiana verdict, but structural argument overwhelming over time
• Realistic downside anchor is $260-$265 (2.8-5.5% decline), not $245 which requires a 23% decline with no clear catalyst
• Upside to re-test of highs plus dividend is approximately 8-12%, not the unfavorable asymmetry the conservative analyst claimed
• Asymmetry is closer to neutral than unfavorable given defensive sector rotation, 6% recession probability, non-hiking Fed, and accelerating JNJ earnings
• Core holding in quality compounder warrants occasional adds at premium prices when structural setup is intact
• Q3 print and talc developments are key catalysts that should govern sizing of incremental adds

→ vs aggressive: Overstates the case—UBS $320 price target is a point estimate, not expected value, and probability of successful execution must be weighted; dismisses declining volume (3.88M vs 7-8M norm) too casually as 'coiled spring' without evidence

→ vs aggressive: Understates talc risk—a fresh Louisiana verdict is not fully priced, and a 10-15% decline is possible even if the stock won't go to zero

→ vs conservative: Two-state calculation is too pessimistic—realistic downside anchor is $260-$265, not $245 which requires a 23% decline with no clear catalyst; the 200 SMA at $233 would require a real rerating event

→ vs conservative: 1.6% upside to upper Bollinger Band versus 5-7% downside to 50 SMA is a snapshot, not probability-weighted; 50 SMA is more likely a pullback zone in an uptrend than start of breakdown given macro setup

→ vs conservative: Treats absence of reason to add as reason not to add—wrong frame for a core holding; occasional adds at premium prices are appropriate when structural setup is intact and sized sensibly

→ vs conservative: Original implementation plan conflates two scenarios—entry at $260 with stop at $267 is a 'stop buy' (breakout confirmation), not a stop loss; proper stop for pullback entry should be below $257, below lower Bollinger Band